Case Report
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jan 27, 2025; 17(1): 99752
Published online Jan 27, 2025. doi: 10.4240/wjgs.v17.i1.99752
Five-year complete remission of super-giant hepatocellular carcinoma with hepatectomy followed by sorafenib plus camrelizumab: A case report
Xiao-Qin Zheng, Li-Bo Sun, Wen-Jie Jin, Hui Liu, Wen-Yan Song, Hui Xu, Ju-Shan Wu, Xiao-Jun Wang, Chun-Yan Gou, Hui-Guo Ding
Xiao-Qin Zheng, Hui Xu, Xiao-Jun Wang, Chun-Yan Gou, Integrated Traditional Chinese and Western Medicine Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
Li-Bo Sun, Ju-Shan Wu, Department of Surgery, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
Wen-Jie Jin, Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona 6500, Ticino, Switzerland
Hui Liu, Department of Pathology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
Wen-Yan Song, Department of Radiology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
Hui-Guo Ding, Department of Gastroenterology and Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
Co-corresponding authors: Chun-Yan Gou and Hui-Guo Ding.
Author contributions: Zheng XQ prepared and wrote the manuscript; Jin WJ and Sun LB drafted and corrected the figures; Xu H collected the data; Wu JS, Liu H, Song WY, and Wang XJ contributed to the design of the report; Ding HG and Gou CY critically revised and edited the manuscript. All authors have read and agreed to the published version of the manuscript. Both Gou CY and Ding HG contributed equally as co-corresponding authors, collaboratively overseeing the study design, data analysis, and interpretation of results. Both authors were equally involved in drafting and revising the manuscript, approving the final version, and are accountable for all aspects of the work, ensuring accuracy and integrity.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui-Guo Ding, Department of Gastroenterology and Hepatology, Beijing Youan Hospital, Capital Medical University, No. 8 Xitoutiao, Youanmenwai, Fengtai District, Beijing 100069, China. dinghuiguo@ccmu.edu.cn
Received: July 29, 2024
Revised: September 23, 2024
Accepted: October 28, 2024
Published online: January 27, 2025
Processing time: 151 Days and 0.7 Hours
Core Tip

Core Tip: Cirrhotic patients with super-giant hepatocellular carcinoma (HCC), accompanied by portal vein invasion, generally have a poor prognosis. We report a patient with super-giant HCC and portal vein invasion, who underwent hepatectomy followed by sorafenib plus camrelizumab, resulting in complete remission for 5 years. However, two critical issues are raised: One is how to screen and manage portal hypertension in HCC, and the other is related to the optimal treatment duration of tyrosine kinase inhibitors and immune checkpoint inhibitors in HCC patients who achieve complete remission. Further research is needed to address these challenges.